Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis

Morales-Lara, María José; Cañete, Juan D.; Torres-Moreno, Daniel; Hernández, M. Victoria; Pedrero, F; Celis, Raquel; García-Simón, María Sergia; Conesa‐Zamora, Pablo

doi:10.1016/j.jbspin.2012.02.003

Cited by 63 publications

(43 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After the full-text review, 10 of these 18 articles were excluded because 2 of them were review articles [16,24], 3 articles had no exact statistics about polymorphisms [25][26][27], 1 reported duplicate data [28], 1 was irrelevant to biological agent [29], 3 were not related to TNFRSF polymorphisms [2,30,31]. Finally, in the current study, 8 eligible studies [32][33][34][35][36][37][38][39] that meet the inclusion criteria were included in our biologic-specific meta-analysis.…”

Section: Studies Included In the Meta-analysismentioning

confidence: 99%

“…The frequency of non-responders ranged from 12.8 to 44.0% (mean 24.11%), and follow-up periods ranged from 14 weeks to 24 months. Among all the eight studies included, seven studies considered the TNFRSF1B polymorphism [32,36,38], and five studies investigated the TNFRSF1A polymorphism [35]. Therefore, seven of the eight studies containing 929 subjects for TNFRSF1B rs1061622 and five of eight studies involving 564 subjects for TNFRSF1A rs767455 were finally analyzed in our meta-analysis.…”

Section: Studies Included In the Meta-analysismentioning

confidence: 99%

See 1 more Smart Citation

The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis

Chen

Wang

et al. 2015

International Immunopharmacology

View full text Add to dashboard Cite

Section: Studies Included In the Meta-analysismentioning

confidence: 99%

Section: Studies Included In the Meta-analysismentioning

confidence: 99%

The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis

Chen

Wang

et al. 2015

International Immunopharmacology

View full text Add to dashboard Cite

“…This study concluded that TRAILR1 626CC (p = 0.048) and TNFR1A 36AA (p = 0.04) genotypes may be associated with beter response after 3 months of inliximab treatment [66].…”

Section: Pharmacogenetics Of Anti-tnfα Treatmentmentioning

confidence: 76%

Pharmacogenetics of Psoriasis Treatment

Redenšek¹,

Dolžan²

2017

An Interdisciplinary Approach to Psoriasis

View full text Add to dashboard Cite

Psoriasis is a chronic systemic, immune-mediated disorder of unknown aetiology, usually presenting with typical inlammatory skin lesions and/or joint manifestations, but systemic inlammation that may lead to the development of co-morbidities may also be present. First-line therapy encompasses local cutaneous treatment and phototherapy, but with more severe symptoms or systemic course, systemic treatment with methotrexate (MTX), immunosuppressant cyclosporine, retinoid acitretin or biologicals may be used. Treatment response varies between patients in terms of eicacy and/or toxicity, which could, among other reasons, be due to genetic diferences between patients. Approximately 10-30% of patients experience adverse drug reactions with MTX treatment, leading to discontinuation of MTX mostly due to hepatotoxicity. Around 15% of patients experience adverse events when treated with biologicals; however, the most frequent reason for discontinuation is ineicacy or loss of the initially favourable response over time. Ineicacy or occurrence of adverse drug reactions cannot be predicted, so genetic biomarkers of drug response in combination with clinical data could be helpful in treatment planning. Several polymorphic genes have already been associated with treatment outcome, most of them involved in drug metabolism, transport and target pathways. Genetic biomarkers could be helpful in personalized care of psoriasis patients in order to prevent adverse events or predict ineicacy of a certain drug.

show abstract

“…Individuals with polymorphisms -676 and -196 were reported to favor response to etanercept [29]. In a study on psoriatic arthritis (PsA), it was found that the TNFR1A, a member of the TNF-receptor superfamily, contributed to response to anti-TNF-alpha treatment, specifically, SNP rs767455 [32]. Individuals homozygous A/A for the SNP rs767455 and PsA were associated with better response to anti-TNF-alpha therapy after 3 months (A/A=88% versus A/G and G/G= 58.9%; P=0.04).…”

Section: Tnf-alpha Genetic Related Findingsmentioning

confidence: 99%

“…This SNP was associated with better response to anti-TNF-α therapy at 3 months (A/A 88% vs A/G and G/G 58.9%) [32] TNFR1A AA The tumor necrosis factor receptor is involved in inflammation and apoptosis, amongst a host of other pathways.…”

Section: Tnf-α Promoter -857mentioning

confidence: 99%

Genetic Influences on Pharmacological Interventions in Psoriasis

Ahmed¹,

Yusuf²

2017

J Clin Exp Dermatol Res

View full text Add to dashboard Cite

Psoriasis is a common chronic inflammatory disease that affects 2% of the population. Therapeutic intervention for psoriasis mainly targets inflammatory cascade through the use of topical agents, phototherapy, systemic agents and the newer biologic agents. The efficacy of many treatments used in psoriasis varies from patient to patient, and some of this variance in response can presumably be attributed to genetic differences. While current research findings are still limited, the clinical utilization of pharmacogenetics allows for tailored treatment plans that have the potential for better response amongst patients as well as conserving expenditures and healthcare resources. In this review, we hope to focus and summarize the conclusions and findings of studies done on the topic of pharmacogenetics in the treatment of psoriasis.

show abstract

Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis

Cited by 63 publications

References 31 publications

The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis

The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis

Pharmacogenetics of Psoriasis Treatment

Genetic Influences on Pharmacological Interventions in Psoriasis

Contact Info

Product

Resources

About